Story

Novo Nordisk Seeks Approval for Oral Wegovy in China, Escalating Rivalry with Eli Lilly

ENTHMSVIIDZHZH-TWJAKOHI
Aug 27, 20261 min read
Novo Nordisk Seeks Approval for Oral Wegovy in China, Escalating Rivalry with Eli Lilly
Text size
Background

Novo Nordisk (NVO) confirmed on Thursday that its application to market an oral version of its weight-loss drug Wegovy has been accepted for review by China’s drug regulator. The move marks a critical step in the company's strategy to capture a larger share of the rapidly growing Chinese market for obesity treatments.

Race for a Lucrative Market

The filing intensifies the competition between Novo Nordisk and its primary rival, Eli Lilly (LLY), in the world's second-largest pharmaceutical market. Both companies are vying for dominance in the GLP-1 drug class, which mimics a gut hormone to suppress appetite and regulate blood sugar.

China presents a significant commercial opportunity, with the country's National Health Commission projecting that the rate of overweight or obese people could exceed 65% by 2030. Drugmakers believe that a daily pill could significantly expand the market by attracting patients who are hesitant to use the current standard of once-weekly injections.

Sample IUX Markets – In-articleAd

Competitive Landscape

Novo Nordisk's move follows a similar filing by its competitor. Eli Lilly submitted a marketing application to Chinese regulators for its own oral GLP-1 drug, orforglipron, at the end of 2025, according to a company statement in March.

Both companies have already secured approvals for their oral medications in other major markets. Novo Nordisk launched its Wegovy pill in the United States this year after receiving early approval, while Eli Lilly secured U.S. approval for orforglipron in April. The competition in China also includes other players like Pfizer and local firm Innovent Biologics, which are developing their own injectable GLP-1 treatments.

Read next

More on Stocks
Back to latest news

LATEST